RxDoctor Payments Data

Timothy Bradshaw

Optometrist · Fredericksburg, VANPI 1457704256

Payments from drug & device makers

$2,012in general payments, 2019–2025

Across 80 payments — averaging $25.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$224
  • Alimera Sciences, Inc.$214
  • Mallinckrodt Hospital Products Inc.$194
  • Aerie Pharmaceuticals, Inc.$170
  • Dompe US, Inc.$169
  • AbbVie$144
  • plus $898 from 18 others

What the payments were for

  • Food & beverage$2,012100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,012 in reported general payments places this provider in the 70th percentile of 1,230 optometrist providers in Virginia.

See all optometrist providers in Virginia

Medicare billing

Part B allowed, 2024
$166,372
Medicare patients
998
Services billed
1,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine20$23,142
LumiganBimatoprost13$9,360
Cyclosporine11$6,575
Brimonidine Tartrate34$3,618
Travoprost13$3,519
Latanoprost243$3,073
Loteprednol Etabonate11$2,558
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$1,958
Prednisolone Acetate25$1,053
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat63$951
Tobramycin-DexamethasoneTobramycin/Dexamethasone22$945
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha67$773
Timolol Maleate58$596
Dorzolamide Hcl12$335
ErythromycinErythromycin Base12$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$144$32,50233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,230 optometrist providers in Virginia.

Other optometrist in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →